[go: up one dir, main page]

GB0418762D0 - Methods and compositions to treat glaucoma - Google Patents

Methods and compositions to treat glaucoma

Info

Publication number
GB0418762D0
GB0418762D0 GBGB0418762.1A GB0418762A GB0418762D0 GB 0418762 D0 GB0418762 D0 GB 0418762D0 GB 0418762 A GB0418762 A GB 0418762A GB 0418762 D0 GB0418762 D0 GB 0418762D0
Authority
GB
United Kingdom
Prior art keywords
compositions
methods
treat glaucoma
glaucoma
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0418762.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomica SA
Original Assignee
Genomica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomica SA filed Critical Genomica SA
Priority to GBGB0418762.1A priority Critical patent/GB0418762D0/en
Publication of GB0418762D0 publication Critical patent/GB0418762D0/en
Priority to ES05781264.6T priority patent/ES2632913T3/en
Priority to LTEP05781264.6T priority patent/LT1781787T/en
Priority to RU2007110646/15A priority patent/RU2407531C2/en
Priority to JP2007529002A priority patent/JP5766900B2/en
Priority to US11/574,169 priority patent/US8030284B2/en
Priority to CA2578064A priority patent/CA2578064C/en
Priority to HUE05781264A priority patent/HUE033977T2/en
Priority to PCT/GB2005/050134 priority patent/WO2006021817A2/en
Priority to PT57812646T priority patent/PT1781787T/en
Priority to SI200532154T priority patent/SI1781787T1/en
Priority to EP05781264.6A priority patent/EP1781787B1/en
Priority to EP10183048A priority patent/EP2298892A3/en
Priority to CN201510697741.4A priority patent/CN105251024A/en
Priority to AU2005276245A priority patent/AU2005276245C1/en
Priority to CNA200580036349XA priority patent/CN101076590A/en
Priority to PL05781264T priority patent/PL1781787T3/en
Priority to CN2012103425305A priority patent/CN102895673A/en
Priority to HRP20171010TT priority patent/HRP20171010T8/en
Priority to EP10183019A priority patent/EP2292757A3/en
Priority to DK05781264.6T priority patent/DK1781787T3/en
Priority to US11/360,305 priority patent/US7592325B2/en
Priority to US12/170,078 priority patent/US8198250B2/en
Priority to US12/170,116 priority patent/US8247387B2/en
Priority to US12/170,132 priority patent/US8258110B2/en
Priority to US12/170,148 priority patent/US8252758B2/en
Priority to US12/170,157 priority patent/US8252759B2/en
Priority to US12/170,104 priority patent/US8247386B2/en
Priority to US12/563,530 priority patent/US7902169B2/en
Priority to US12/874,928 priority patent/US8389490B2/en
Priority to JP2012157548A priority patent/JP2012205594A/en
Priority to US13/744,881 priority patent/US8951982B2/en
Priority to CY20171100719T priority patent/CY1119061T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0418762.1A 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma Ceased GB0418762D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB0418762.1A GB0418762D0 (en) 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma
DK05781264.6T DK1781787T3 (en) 2004-08-23 2005-08-23 TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS
PL05781264T PL1781787T3 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
CN2012103425305A CN102895673A (en) 2004-08-23 2005-08-23 Treatment of eye disorders
RU2007110646/15A RU2407531C2 (en) 2004-08-23 2005-08-23 siPHK-BASED TREATMENT OF EYE DISEASE CHARACTERISED BY HIGH INTRAOCULAR PRESSURE
JP2007529002A JP5766900B2 (en) 2004-08-23 2005-08-23 Treatment of eye diseases characterized by elevated intraocular pressure with siRNA
US11/574,169 US8030284B2 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
CA2578064A CA2578064C (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
HUE05781264A HUE033977T2 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
PCT/GB2005/050134 WO2006021817A2 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
PT57812646T PT1781787T (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
SI200532154T SI1781787T1 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
EP05781264.6A EP1781787B1 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
EP10183048A EP2298892A3 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
CN201510697741.4A CN105251024A (en) 2004-08-23 2005-08-23 Treatment of eye disorders
AU2005276245A AU2005276245C1 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated introacular pressure by siRNAs
CNA200580036349XA CN101076590A (en) 2004-08-23 2005-08-23 Treatment of eye diseases characterized by elevated intraocular pressure with siRNA
ES05781264.6T ES2632913T3 (en) 2004-08-23 2005-08-23 Treatment with mRNA of eye disorders characterized by elevated intraocular pressure
EP10183019A EP2292757A3 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
LTEP05781264.6T LT1781787T (en) 2004-08-23 2005-08-23 TREATMENT OF EYE DISORDERS CHARACTERIZED BY AN ELEVATED INTRAOCULAR PRESSURE BY siRNAS
HRP20171010TT HRP20171010T8 (en) 2004-08-23 2005-08-23 Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
US11/360,305 US7592325B2 (en) 2004-08-23 2006-02-22 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,104 US8247386B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,157 US8252759B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,116 US8247387B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,078 US8198250B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,148 US8252758B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/170,132 US8258110B2 (en) 2004-08-23 2008-07-09 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/563,530 US7902169B2 (en) 2004-08-23 2009-09-21 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
US12/874,928 US8389490B2 (en) 2004-08-23 2010-09-02 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
JP2012157548A JP2012205594A (en) 2004-08-23 2012-07-13 TREATMENT OF EYE DISORDER CHARACTERIZED BY ELEVATED INTRAOCULAR PRESSURE BY siRNA
US13/744,881 US8951982B2 (en) 2004-08-23 2013-01-18 Methods and compositions for the treatment of eye disorders with increased intraocular pressure
CY20171100719T CY1119061T1 (en) 2004-08-23 2017-07-05 EYE DISEASE TREATMENT FEATURED BY INCREASED INTER-OCLUSIVE PRESSURE WITH SIRNAS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0418762.1A GB0418762D0 (en) 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma

Publications (1)

Publication Number Publication Date
GB0418762D0 true GB0418762D0 (en) 2004-09-22

Family

ID=33042492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0418762.1A Ceased GB0418762D0 (en) 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma

Country Status (2)

Country Link
CN (1) CN101076590A (en)
GB (1) GB0418762D0 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103361353B (en) * 2013-07-19 2016-04-20 暨南大学 Tsiklomitsin aptamers and the aptamers electrochemica biological sensor detecting tsiklomitsin
CN119530218A (en) * 2023-08-30 2025-02-28 苏州炫景生物科技有限公司 Double-stranded oligonucleotides and their application in inhibiting the expression of angiotensinogen
CN118440938B (en) * 2023-04-27 2025-07-08 成都先衍生物技术有限公司 A siRNA targeting AGT gene expression and its conjugate and use
WO2025036511A1 (en) * 2023-08-16 2025-02-20 成都国为生物医药有限公司 Sirna, sirna conjugate, pharmaceutical composition and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495120B1 (en) * 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
CA2504926C (en) * 2002-11-01 2014-01-14 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of hif-1 alpha

Also Published As

Publication number Publication date
CN101076590A (en) 2007-11-21

Similar Documents

Publication Publication Date Title
EP1737482A4 (en) Compositions and methods for treating diseases
SI1791791T1 (en) Methods and compositions for treatment of water
PT3006040T (en) Methods and compositions for treating neuropathies
IL191072A0 (en) Therapeutic compositions and methods
EP1809272A4 (en) Methods and compositions for treatment of free radical injury
GB2423928B (en) Methods and compositions for treating pain
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1827362A4 (en) Compositions and methods of their use for improving the condition and appearance of skin
ZA200700918B (en) Compositions and methods for treating eye disorders and conditions
LT2444079T (en) Compositions and Methods for Treatment of Eye Disorders
IL190885A0 (en) Immunogenic compositions and methods of use
ZA200508655B (en) Compositions and methods relating to stop-1
EP1786265A4 (en) Novel compositions and methods of treatment
PL2056799T3 (en) Compositions and methods for treating or preventing glaucoma or progression thereof
IL180195A0 (en) Aequorin-containing compositions and methods of using same
GB0418762D0 (en) Methods and compositions to treat glaucoma
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
AU2003263988A8 (en) Methods and compositions to treat conditions associated with neovascularization
EP1811846A4 (en) Methods for making and using synergistic multifunctional compositions
EP1781318A4 (en) Methods and compositions for the treatment of polycystic diseases
GB0504657D0 (en) Compositions and methods of treatment
GB0503412D0 (en) Methods and compositions to treat glaucoma
GB0419175D0 (en) Method of treatment and compositions
GB0506612D0 (en) Methods and compositions to treat asthma
GB0506299D0 (en) Methods and compositions to treat asthma

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)